Verona Pharma plc
VRNA
Rang in aandelen
#2233
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aandeelprijs
$106.91
Laatst gesynchroniseerd: 2025-10-07
Marktkapitalisatie
$9.09B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Categorie
Healthcare
Winst voor Verona Pharma plc (VRNA)
Winst in Jun 2025 TTM: $-56.52M
Volgens de meest recente financiële verslagen van Verona Pharma plc bedraagt de huidige winst van het bedrijf $-56.52M. In 2023 behaalde het bedrijf een winst van $-42.28M, een stijging ten opzichte van de winst van 2022, die $-56.62M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Verona Pharma plc van 2005 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-56.52M | -56.62% |
| 2024 | $-130.30M | 208.20% |
| 2023 | $-42.28M | -25.33% |
| 2022 | $-56.62M | 37.75% |
| 2021 | $-41.10M | -13.52% |
| 2020 | $-47.53M | 17.27% |
| 2019 | $-40.53M | 31.86% |
| 2018 | $-30.74M | -9.75% |
| 2017 | $-34.06M | 362.02% |
| 2016 | $-7.37M | -44.44% |
| 2015 | $-13.27M | 126.33% |
| 2014 | $-5.86M | 25.78% |
| 2013 | $-4.66M | 75.08% |
| 2012 | $-2.66M | -40.09% |
| 2011 | $-4.44M | -2.04% |
| 2010 | $-4.54M | 8.38% |
| 2009 | $-4.18M | 45.74% |
| 2008 | $-2.87M | -40.29% |
| 2007 | $-4.81M | 105.89% |
| 2006 | $-2.34M | -3,133.92% |
| 2005 | $76.99K | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -9,432.91% |
US
|
|
| $-3.09B | 5,361.85% |
US
|
|
| $-4.02B | 7,005.88% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,551.30% |
NL
|
